As of today (2024-04-19), the Forward Annual Dividend Yield of Sorrento Therapeutics is 0.00%.
As of today (2024-04-19), the Trailing Annual Dividend Yield of Sorrento Therapeutics is 0.00%.
SRNE's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.59 * Ranked among companies with meaningful Forward Dividend Yield % only.
Sorrento Therapeutics's Dividends per Share for the
three
months ended in Jun. 2023 was $0.00.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Competitive Comparison
For the Biotechnology subindustry, Sorrento Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sorrento Therapeutics Forward Dividend Yield % Distribution
For the Biotechnology industry and Healthcare sector, Sorrento Therapeutics's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Sorrento Therapeutics's Forward Dividend Yield % falls into.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Sorrento Therapeutics Forward Dividend Yield % Related Terms
Thank you for viewing the detailed overview of Sorrento Therapeutics's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Sorrento Therapeutics (Sorrento Therapeutics) Business Description
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SRNE has been successfully added to your